SPRINTR is designed to be easily integrated into everyday clinical practice. The approach can be adapted to the conditions at participating clinics.
Here, you will find practical information on how to include patients, where to find materials for information and consent, as well as how sampling and data collection are carried out. You will also find contact information for those responsible for the study.
SPRINTR – a study integrated into clinical routine The men being investigated for suspected prostate cancer receive an invitation to the study along with an invitation to a biopsy. Information materials and consent forms are sent electronically as PDFs via the medical record system/1177 or by traditional mail. Men who do not have suspected prostate cancer but have taken a PSA test, or men with confirmed prostate cancer, can also be invited. Obtaining consent can be done in various ways. After reading the research subject information and having the opportunity to ask questions, the research subject can consent entirely on their own using a QR code and Bank-ID, or get help from clinic staff to consent digitally. If there are obstacles to using the electronic consent tool, a signed consent form can be provided. Consent must be recorded in the medical record. Integration with RCC's study database (INCA EDC) for manual consent recording is under development.
Sampling in the study involves biopsies taken according to clinical routine, which can then be used for various staining and RNA/DNA analyses. It is also possible to start biobanking of blood and urine for research purposes during diagnosis or follow-up. These samples are managed via SIB (healthcare-integrated biobanking) and registered in Biobank North. As a healthcare professional, you play a vital role in building a national infrastructure for future biomarker-driven treatment studies.
